Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Sridevi Rajeeve is a hematologist-oncologist and physician-researcher specializing in plasma cell disorders and cellular therapies. Along with colleagues at Memorial Sloan-Kettering Cancer Center (MSK). Dr. Rajeeve offers a range of treatment options, including standard-of-care medications and cutting-edge clinical trials.

Blood Cancers OncTalk 2024
The Blood Cancers OncTalk was a live, virtual, interactive patient education event hosted in October 2024 that included presentations and panel discussions covering general subjects relevant to a diverse range of blood cancers and treatment options and an opportunity to speak with the experts in a Q&A session.
Author
Sridevi Rajeeve, MD - Guest Faculty
Image
Blood Cancers OncTalk 2024

 

This event was moderated by Dr. Sridevi Rajeeve, Memorial Sloan Kettering, joined by speakers: Dr. Hamza Hashmi, Memorial Sloan Kettering, Dr. Michele Stanchina, University of Miami, Dr. Muhammad Salman Faisal, Oklahoma University, and Dr. Andrew Srisuwananukorn, Ohio State University

Topics include:

- Myeloma 101: Facts and Fiction of the 'Myeloma Marathon'

- Updates in DLBCL

- Treatment Basics of Bone Marrow Transplant

- Frontline Therapies in Myelofibrosis

- Panel Discussions and a Question-and-Answer session

To watch the complete playlist, click here.

 

 

 

 

Video Language

Next Previous link

Previous Post

Related Content

Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.

Forum Discussions

Hi Stan,

It's so good to hear you and yours are doing well and that you were able to spend time with both families for Thanksgiving.  I know it meant a...

Hi Stan!  It is good to hear from you -- I am so very happy you are doing well.  I agree with Janine that family and friends - our chosen family...

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Recent Comments

JOIN THE CONVERSATION
So good to hear from you Stan
By dbrock on
Hi Stan,

It's so good to…
By JanineT GRACE … on
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on